Musculoskeletal Tumour Biopsy — Principles & Technique

The Central Principle The biopsy is the most important and most commonly mishandled step in the management of a musculoskeletal tumour. A technically perfect resection cannot rescue a patient from a badly-placed biopsy that has contaminated tissue planes, an uninvolved compartment, or a neurovascular bundle. The governing rule is that the biopsy must be performed by, or in direct discussion with, the surgeon who will perform the definitive resection, at the specialist sarcoma / multidisciplinary team (MDT) centre. ### Mankin's Evidence — Why the Centre Matters The landmark studies by Mankin and colleagues remain the cornerstone evidence: - Mankin et al. (1982) PMID 7130225 — original Musculoskeletal Tumor Society survey of 329 biopsies: troubling rates of error in diagnosis and technique, with complications that adversely affected patient care, occurring far more often when biopsy was done at the referring rather than the treating institution.

• Mankin et al. (1996) PMID 8642021 — repeat study (597 patients from 21 institutions) showed the problem had not improved: the overall diagnostic error rate was 17.8%; a biopsy problem forced a different, often more complex operation in 19.3%; the course/outcome changed (more complex resection, disability, local recurrence or death) in 10.1%; and 18 patients had an unnecessary amputation attributable to the biopsy. Errors, complications and changes in course/outcome were 2 to 12 times greater (p less than 0.001) when the biopsy was done in a referring institution rather than a treatment centre. The conclusion of both studies: refer the patient with the lesion intact; biopsy at the centre that will treat the patient. ## Indications for Biopsy A biopsy is performed to obtain a tissue diagnosis that will determine definitive treatment, once clinical assessment and staging imaging raise concern for a primary bone or soft-tissue tumour. ### When Biopsy is Indicated - Any soft-tissue mass that is deep to fascia, greater than 5 cm, enlarging, or symptomatic — treat as sarcoma until proven otherwise
• An aggressive or indeterminate bone lesion on imaging (cortical destruction, periosteal reaction, soft-tissue extension, indeterminate matrix)
• Suspected primary bone sarcoma (osteosarcoma, Ewing sarcoma, chondrosarcoma)
• A solitary destructive bone lesion in an adult where metastasis or myeloma is possible but a tissue diagnosis is required (after screening for a known primary)
• Confirmation of metastatic disease where it would change management and the primary is unknown or in doubt ### When Biopsy May Be Deferred or Avoided - Classic benign latent lesions with pathognomonic imaging (non-ossifying fibroma, classic osteochondroma, simple bone cyst, classic enchondroma) — observe; biopsy is not required
• Lesions where the diagnosis is established radiologically by the MDT (e.g. typical osteoid osteoma treated directly)
• A known primary carcinoma with multiple typical bone metastases — biopsy of the most accessible lesion only if it will alter management ### Sequence — Biopsy is the LAST Step The biopsy must follow, not precede, the staging work-up: 1. History, examination, plain radiographs

2. Staging imaging completed first — whole-bone MRI with contrast (local stage, skip lesions), CT chest (pulmonary metastases), bone scan / FDG-PET as indicated
3. MDT discussion of imaging and a definitive surgical plan
4. Biopsy performed last, with the tract chosen to fit the planned resection Performing the biopsy before staging imaging produces haematoma and oedema that distort the MRI, can over-stage the lesion, and may render the imaging uninterpretable for resection planning. ## Staging Imaging — Why It Must Precede the Biopsy All staging imaging must be complete and reviewed before the biopsy, for three reasons: 1. Avoid distortion — a biopsy creates haematoma, oedema and a needle tract that contaminate the MRI signal and obscure true tumour margins
5. Target the biopsy — contrast MRI and PET identify the viable, enhancing periphery (where representative tissue lies) and the necrotic centre (to avoid)
6. Plan the tract — cross-sectional imaging defines compartmental anatomy and the neurovascular bundle, allowing a safe corridor to be chosen

Fine needle aspiration (FNA) yields cytology only — no tissue architecture, limited grading and subtyping. It reliably triages benign versus malignant and is useful for confirming recurrence or metastasis when the diagnosis is already known, but it is not adequate as the primary diagnostic biopsy of a new suspected sarcoma. Excisional biopsy is appropriate only for small, superficial, clearly benign or low-grade lesions; removing a sarcoma whole as a "biopsy" contaminates the entire bed and is forbidden for a suspected high-grade or deep sarcoma.

The goal of the operation is to obtain a representative, diagnostic tissue sample with the lowest possible contamination and morbidity, with every step — sequence, site, orientation, technique, haemostasis, specimen handling and documentation — made to protect the option of limb salvage and an accurate diagnosis. The exposure is the biopsy tract itself: it is planned jointly with the definitive surgeon, laid out before any tissue is taken, and treated throughout as a contaminated extension of the tumour that will be excised en bloc.

View larger

View larger

View larger

After the Biopsy — Specimen, Documentation & MDT Handling the specimen. Send fresh tissue promptly to pathology — the specialist sarcoma pathologist may need fresh material for cytogenetics and molecular studies (for example translocation studies in Ewing sarcoma and synovial sarcoma). Send tissue for histology AND microbiology in every case, because infection is the principal differential of a destructive bone lesion. Frozen section intra-operatively confirms that diagnostic lesional tissue has been obtained before the patient leaves theatre (it does not give the final diagnosis). Ensure adequate tissue for immunohistochemistry and molecular testing. Documentation and marking. Document and mark the tract (skin tattoo and a clear operative note) so the definitive surgeon excises it en bloc with the specimen. Photograph and record the entry point — a forgotten or undocumented tract may be left behind and act as a focus for recurrence. Multidisciplinary team (MDT) review. The biopsy result is interpreted in the specialist sarcoma MDT, where the radiologist, pathologist and surgeon correlate imaging, histology and clinical findings — discordance triggers re-review or re-biopsy. The definitive plan is set: neoadjuvant chemotherapy (e.g. osteosarcoma, Ewing sarcoma), radiotherapy, and the type and timing of resection. The margin required is defined (intralesional / marginal / wide / radical per Enneking) and the resection includes the biopsy tract. Radiology–pathology discordance. If the histology does not fit the imaging (for example, benign-looking histology from an aggressive-looking lesion), the result is treated as non-diagnostic / sampling error, not reassurance. The MDT re-reviews and the patient is re-biopsied rather than discharged. ## Complications of a Poorly-Planned Biopsy The complications of biopsy are overwhelmingly the consequence of poor planning and technique — and many are catastrophic for the patient's oncological outcome.

• Transverse incision — contaminates the whole limb width; longitudinal only.
• Crossing compartments / NV bundles — converts salvage to sacrifice.
• Biopsy before staging imaging — distorts the MRI and ruins resection planning.
• Excisional biopsy of a sarcoma — turns the whole bed into a contaminated tract.
• Failure to send microbiology — infection is the great mimic; always culture as well as biopsy.
• Sampling the necrotic centre — non-diagnostic; target the viable periphery. The biopsy is part of a continuum that begins with referral to the sarcoma centre and ends with en-bloc excision of the tract at definitive surgery. Every decision is made to protect the option of limb salvage and an accurate diagnosis.

Surgical Staging of Musculoskeletal Sarcoma The staging systems are presented here for background — they are what the MDT uses to define the surgical margin required, and they explain why the biopsy tract is treated as a contaminated extension of the tumour that must be excised en bloc within an adequate margin. ### Enneking (Surgical Staging System — MSTS) The Enneking system stages musculoskeletal sarcomas by surgical grade (G), anatomical site/compartment (T) and metastasis (M), and directly drives the surgical margin required — intralesional, marginal, wide or radical.